Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003;8(4):335-41. Abstract

Buzdar A et al. Phase III, multicenter, doubleblind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19(14):3357- 66. Abstract

Buzdar AU et al. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: A review of data from first-line metastatic disease trials in postmenopausal women. Breast J 2004;10(3):211-7. Abstract

Carlson RW. Sequencing of endocrine therapies in breast cancer — integration of recent data. Breast Cancer Res Treat 2002;75(Suppl 1):27-32. Abstract

Carlson RW, Henderson IC. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat 2003;80(Suppl 1):19-26. Abstract

Dixon JM. Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert Opin Pharmacother 2004(2):307-16. Abstract

Forward DP et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4. Abstract

Gradishar WJ, Morrow M. Advances in endocrine therapy of metastatic breast cancer. Br J Surg 2002;89(12):1489-92. No abstract available.

Higa GM. Exemestane: treatment of breast cancer with selective inactivation of aromatase. Am J Health Syst Pharm 2002;59(22):2194-201; quiz 2202-4. Abstract

Hortobagyi GN. The status of breast cancer management: challenges and opportunities. Breast Cancer Res Treat 2002;75(Suppl 1):61-5. Abstract

Howell A et al. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 2003;82(3):215-22. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract

Howell SJ et al. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18(1):47-66. Abstract

Ingle JN. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004;10(1 Pt 2):362S-7S. Abstract

Ingle JN, Suman VJ. Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings. J Steroid Biochem Mol Biol 2003;86(3-5):313-9. Abstract

Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004;90(Suppl 1):15-8. Abstract

Jones SE. Fulvestrant: An estrogen receptor antagonist that downregulates the estrogen receptor. Semin Oncol 2003;30(5 Suppl 16):14-20. Abstract

Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 2002;24(Suppl A):3-16. Review. Erratum in: Clin Ther 2002 Apr;24(4):717. Clin Ther 2002;24(6):1017. Abstract

Lipton A et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20(6):1467-72. Abstract

Lonning PE. The role of aromatase inactivators in the treatment of breast cancer. Int J Clin Oncol 2002;7(4):265-70. Abstract

Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract

Montemurro F et al. Factors affecting progression- free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 2002;29(10):861- 6. Abstract

Morris C, Wakeling A. Fulvestrant (‘Faslodex’) — a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002(4):267-76. Abstract

Mouridsen H, Gershanovich M. The role of aromatase inhibitors in the treatment of metastatic breast cancer. Semin Oncol 2003;30(4 Suppl 14):33-45. Abstract

Mouridsen H et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(11):2101-9. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

Osborne CK et al. Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004;90(Suppl 1):2-6. Abstract

Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther 2002;24(Suppl C):43-57. Abstract

Piccart M et al. Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Ann Oncol 2003;14(7):1017-25. Abstract

Piccart MJ et al. Letrozole’s superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer. Eur J Cancer 2002;38(Suppl 6):52-4. No abstract available.

Pritchard KI. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res 2003;9(1 Pt 2):460S-7S. Abstract.

Robertson JF. Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer. Clin Ther 2002;24(Suppl A):17-30. Abstract

Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol 2003;26(Suppl 4):9- 16. Abstract

Rose C et al. An open randomised trial of secondline endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39(16):2318- 27. Abstract

Sainsbury R. Aromatase inhibition in the treatment of advanced breast cancer: Is there a relationship between potency and clinical efficacy? Br J Cancer 2004;90:1733-39. Abstract

Sundar S et al. Management of endocrine resistant breast cancer. J Br Menopause Soc 2004;10(1):16- 23. Abstract

Thurlimann B et al. Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95 — a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004;85(3):247-54. Abstract

Vergote I et al; Trial 0020 Investigators; Trial 0021 Investigators. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract

Wilcken N et al. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003;(2):CD002747. Abstract